Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs.
about
Design, synthesis, and evaluation of potent and selective ligands for the dopamine 3 (D3) receptor with a novel in vivo behavioral profileWhat can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease?Recent methods for measuring dopamine D3 receptor occupancy in vivo: importance for drug developmentCJ-1639: A Potent and Highly Selective Dopamine D3 Receptor Full AgonistHow antipsychotics work-from receptors to reality.Antipsychotic drug action: targets for drug discovery with neurochemical imaging.Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study.A series of 18F-labelled pyridinylphenyl amides as subtype-selective radioligands for the dopamine D3 receptor.Implication of dopamine D3 receptor activation in the reversion of Parkinson's disease-related motivational deficits.Binding of pramipexole to extrastriatal dopamine D2/D3 receptors in the human brain: a positron emission tomography study using 11C-FLB 457.Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626.Eating high-fat chow increases the sensitivity of rats to quinpirole-induced discriminative stimulus effects and yawning.Pramipexole derivatives as potent and selective dopamine D(3) receptor agonists with improved human microsomal stability.Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists.Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compoundDose-response analysis of locomotor activity and stereotypy in dopamine D3 receptor mutant mice following acute amphetamine.Novel antipsychotics in schizophrenia.Signaling mechanisms of the D3 dopamine receptor.The search for novel antipsychotics: pharmacological and molecular targets.You are what you eat: influence of type and amount of food consumed on central dopamine systems and the behavioral effects of direct- and indirect-acting dopamine receptor agonists.High-affinity and selective dopamine D₃ receptor full agonistsComparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds.Interaction of D₃ preferring agonist (-)-N⁶-(2-(4-(biphenyl-4-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264) with cloned human D₂L, D₂S, and D₃ receptors: potent stimulation of mitogen-activated protein kinA pivotal role of FOS-mediated BECN1/Beclin 1 upregulation in dopamine D2 and D3 receptor agonist-induced autophagy activation.The potential role of dopamine D₃ receptor neurotransmission in cognition.What about temperature? Haloperidol-induced hypotermia.Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor.Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on L-dopa dependent animal involuntary movements in rats.Molecular mapping of striatal subdivisions in juvenile Macaca Mulata.Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond.Computational Study and Modified Design of Selective Dopamine D3 Receptor Agonists.Dopamine D3 receptor selective ligands with varying intrinsic efficacies at adenylyl cyclase inhibition and mitogenic signaling pathways.Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors.Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex.Positron emission tomography imaging of dopamine D2 receptors using a highly selective radiolabeled D2 receptor partial agonist.Effect of cyclosporin A on the uptake of D3-selective PET radiotracers in rat brain.Endogenous dopamine (DA) competes with the binding of a radiolabeled D₃ receptor partial agonist in vivo: a positron emission tomography studyEffects of selective dopamine receptor subtype agonists on cardiac contractility and regional haemodynamics in rats.Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.
P2860
Q24651049-88CD449C-D438-4B9C-97AA-9F8E8A58D656Q26767268-80E3D279-16A8-4AB4-9FF9-764FB3524361Q27014737-4F8A06BB-6154-4B76-8D4B-F3D7A77B626AQ28254222-C736F0D6-BBD4-4A9A-8C6F-26739718D63AQ30457477-4ABB6772-D6D9-4BCA-913C-97D9ADB1D286Q31032036-CD735085-F17F-4780-8C7B-CD65B7A358F9Q33465315-5C3C55CC-5B44-47AB-A66F-7647B6D1410FQ33560926-FC5FC64F-D526-4A5B-8A51-37924637E5E9Q33840503-2E49509E-3BE3-4599-B64F-7DD9EAF011B6Q33847160-7AF42BB9-FC7D-432C-915D-896E93978893Q33947433-28062A29-A832-41BE-9064-4C0A6B599827Q34158231-93964ACD-8566-4BE2-AD01-A62B96C0ED8EQ34241047-3F23D258-06DA-497E-B54F-D9FF4096A0ACQ34775660-10C9A08D-48BC-4E6D-AB4F-FD7873BFA3DEQ34982537-DCF876F9-2AFF-4CF4-B949-69AAF05504DCQ35055114-5CA991C8-32A2-429F-9BFA-4CE5624CAC5CQ35669953-AE4D20BB-49B4-4905-9500-CC5497B05A16Q35753453-73499747-DCBA-4299-AA7A-950D539485C4Q35936704-6C188E11-BAEC-400A-853A-2CBBBCDF221DQ35976379-EFF08079-CBC4-44F9-A316-915728843A4BQ36045250-D2B163D7-DD9A-47E6-92BA-DE01C22D5052Q36288428-5E14DCFF-EF12-4275-98D9-CBFC7A5E9DB6Q36479708-CF1F6D24-8E9E-4227-97A5-420AD347BFF8Q36575989-9E624534-4AB9-4492-A3DE-E3AB5D7DD83FQ36777200-62308600-A068-4E01-94D5-41099C91054AQ37106827-B5C86471-A868-4CD8-8516-378CF74A30DBQ37223701-12648715-6646-4DD3-B6D6-D357F0A0CECAQ37239341-B6430EBB-0E31-4825-8AA3-4F857038B37FQ37286549-409F5A6D-1FA2-41CB-8F57-CBEBB827522DQ37360956-38E1D270-9126-4115-AC8D-B8E4A874C29CQ38447289-1D04FB24-BE92-4792-8D67-639AD267050FQ38911479-C4057CEF-7005-46E8-B01C-04FAD03C16C0Q39772838-F4815FBA-42FA-46D9-BD50-883328418641Q40070459-96B2C562-48F5-4BFC-A951-84BB91571B02Q40496424-3BB34730-F4FD-4236-8478-3CD6FE382529Q41998180-D362404C-0360-4DF8-A6B0-0EABFE86CFE4Q42035376-D21798F5-D710-4221-A0F3-67154E1E8E0DQ42745808-4C95E4CA-4798-4DA2-B7B3-14D2721B7F67Q45230121-E03633F4-3FCA-4D52-AE9F-A8DE0C196B5EQ46157390-84F00F2E-AC40-4BA2-B1B1-58331D972388
P2860
Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Dopamine D3 receptor as a ther ...... ic and antiparkinsonian drugs.
@ast
Dopamine D3 receptor as a ther ...... ic and antiparkinsonian drugs.
@en
Dopamine D3 receptor as a ther ...... ic and antiparkinsonian drugs.
@nl
type
label
Dopamine D3 receptor as a ther ...... ic and antiparkinsonian drugs.
@ast
Dopamine D3 receptor as a ther ...... ic and antiparkinsonian drugs.
@en
Dopamine D3 receptor as a ther ...... ic and antiparkinsonian drugs.
@nl
prefLabel
Dopamine D3 receptor as a ther ...... ic and antiparkinsonian drugs.
@ast
Dopamine D3 receptor as a ther ...... ic and antiparkinsonian drugs.
@en
Dopamine D3 receptor as a ther ...... ic and antiparkinsonian drugs.
@nl
P1476
Dopamine D3 receptor as a ther ...... ic and antiparkinsonian drugs.
@en
P2093
P304
P356
10.1016/S0163-7258(01)00139-5
P577
2001-05-01T00:00:00Z